Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) Non Operating Income (2021 - 2025)

Prime Medicine (PRME) has disclosed Non Operating Income for 5 consecutive years, with -$4.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 1.46% year-over-year to -$4.5 million, compared with a TTM value of $148000.0 through Dec 2025, up 212.98%, and an annual FY2025 reading of $148000.0, up 260.98% over the prior year.
  • Non Operating Income was -$4.5 million for Q4 2025 at Prime Medicine, down from $3.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $7.3 million in Q4 2022 and bottomed at -$8.4 million in Q3 2021.
  • Average Non Operating Income over 5 years is $479588.2, with a median of $434000.0 recorded in 2023.
  • Peak annual rise in Non Operating Income hit 3886.05% in 2024, while the deepest fall reached 253.27% in 2024.
  • Year by year, Non Operating Income stood at -$8.4 million in 2021, then surged by 187.91% to $7.3 million in 2022, then plummeted by 59.16% to $3.0 million in 2023, then plummeted by 253.27% to -$4.6 million in 2024, then increased by 1.46% to -$4.5 million in 2025.
  • Business Quant data shows Non Operating Income for PRME at -$4.5 million in Q4 2025, $3.4 million in Q3 2025, and $1.3 million in Q2 2025.